NZ598783A - Use of opioid receptor antagonist for gastrointestinal tract disorders - Google Patents

Use of opioid receptor antagonist for gastrointestinal tract disorders

Info

Publication number
NZ598783A
NZ598783A NZ598783A NZ59878310A NZ598783A NZ 598783 A NZ598783 A NZ 598783A NZ 598783 A NZ598783 A NZ 598783A NZ 59878310 A NZ59878310 A NZ 59878310A NZ 598783 A NZ598783 A NZ 598783A
Authority
NZ
New Zealand
Prior art keywords
gastrointestinal tract
receptor antagonist
opioid receptor
tract disorders
opioid
Prior art date
Application number
NZ598783A
Other languages
English (en)
Inventor
Richard M Woodward
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ598783(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of NZ598783A publication Critical patent/NZ598783A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ598783A 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders NZ598783A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24361609P 2009-09-18 2009-09-18
PCT/US2010/049311 WO2011035142A1 (en) 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders

Publications (1)

Publication Number Publication Date
NZ598783A true NZ598783A (en) 2013-07-26

Family

ID=43216894

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598783A NZ598783A (en) 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders

Country Status (19)

Country Link
US (1) US20110071163A1 (https=)
EP (1) EP2477627B1 (https=)
JP (1) JP5797655B2 (https=)
KR (1) KR20120092592A (https=)
CN (2) CN104958298A (https=)
AU (1) AU2010295464B2 (https=)
BR (1) BR112012006069A8 (https=)
CA (1) CA2774021A1 (https=)
CL (1) CL2012000676A1 (https=)
CO (1) CO6531453A2 (https=)
HK (1) HK1210959A1 (https=)
IL (1) IL218679A0 (https=)
MX (1) MX342548B (https=)
NZ (1) NZ598783A (https=)
PE (1) PE20120991A1 (https=)
RU (1) RU2561873C2 (https=)
TW (1) TW201118084A (https=)
WO (1) WO2011035142A1 (https=)
ZA (1) ZA201201954B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102571A1 (en) * 2012-12-28 2014-07-03 Instytut Medycyny Doswiadczalnej I Klinicznej Im. Miroslawa Mossakowskiego Polskiej Akademii Nauk Peptidomimetics and their application
TN2018000355A1 (en) 2016-05-20 2020-06-15 Esteve Pharmaceuticals Sa Tetrahydropyran and thiopyran derivatives having multimodal activity against pain.
CN106117190B (zh) * 2016-06-21 2019-03-29 山东川成医药股份有限公司 一种倍福普兰的合成方法
CN113573711A (zh) 2019-01-04 2021-10-29 伊瑟治疗公司 治疗药物或酒精依赖性的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US5064834A (en) * 1987-04-16 1991-11-12 Eli Lilly And Company Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0759303B1 (en) 1994-04-22 2002-10-16 Yamanouchi Pharmaceutical Co. Ltd. Colon-specific drug release system
US5378448A (en) * 1994-06-07 1995-01-03 Lin; Hsing K. Process for removing selenium from sulfur
TW490465B (en) * 1994-11-24 2002-06-11 Janssen Pharmaceutica Nv Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
AU776567B2 (en) * 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
ATE406360T1 (de) * 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
CA2549009A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
ES2390459T3 (es) * 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
ATE399164T1 (de) * 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
DE602005022572D1 (de) * 2004-03-12 2010-09-09 Lilly Co Eli Antagonisten des opioidrezeptors
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
MX2008009650A (es) * 2006-01-24 2008-11-06 R Tech Ueno Ltd Formulacion de capsula de gelatina suave.
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
EP2214672B1 (en) * 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
RU2482107C2 (ru) * 2007-12-11 2013-05-20 Тереванс, Инк. Производные 3-карбоксипропил-аминотетралина и родственные соединения в качестве антагонистов mu-опиоидного рецептора
JP5650657B2 (ja) * 2008-12-10 2015-01-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−カルボキシプロピル−アミノテトラリン化合物の結晶形態
TR201908514T4 (tr) * 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇

Also Published As

Publication number Publication date
ZA201201954B (en) 2012-11-28
JP2013505260A (ja) 2013-02-14
MX342548B (es) 2016-10-04
EP2477627B1 (en) 2018-08-15
EP2477627A1 (en) 2012-07-25
AU2010295464A1 (en) 2012-04-12
PE20120991A1 (es) 2012-08-01
BR112012006069A8 (pt) 2017-10-10
IL218679A0 (en) 2012-05-31
WO2011035142A1 (en) 2011-03-24
MX2012003310A (es) 2012-07-17
JP5797655B2 (ja) 2015-10-21
CO6531453A2 (es) 2012-09-28
AU2010295464B2 (en) 2015-11-26
CN102695508A (zh) 2012-09-26
TW201118084A (en) 2011-06-01
HK1210959A1 (en) 2016-05-13
CN104958298A (zh) 2015-10-07
RU2012115450A (ru) 2013-10-27
CL2012000676A1 (es) 2012-10-19
KR20120092592A (ko) 2012-08-21
CA2774021A1 (en) 2011-03-24
RU2561873C2 (ru) 2015-09-10
BR112012006069A2 (pt) 2016-03-29
US20110071163A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX356032B (es) Compuestos indola y métodos para tratar el dolor visceral.
MX2009010759A (es) Derivados de carboxamida imidazolidina como modulares de p2x7.
MX2012004848A (es) Compuestos heterociclicos triciclicos.
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
JO3434B1 (ar) مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
NZ589733A (en) Oral administration of peripherally-acting opioid antagonists
IL193252A0 (en) N-hydroxyacrylamide compounds
MY154591A (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
NZ605431A (en) D2 antagonists, methods of synthesis and methods of use
NZ598783A (en) Use of opioid receptor antagonist for gastrointestinal tract disorders
MY148084A (en) Substituted carboxamides as group i metabotropic receptor antagonists
MX2013006768A (es) Moduladores de receptor de glucagon.
MX2012007005A (es) Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5.
WO2007114902A3 (en) Alkylthiobenzylpiperidine compounds
WO2011080502A3 (en) New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2007114916A3 (en) Arylbenzylpiperidine compounds
MX2012007006A (es) Tiazoles biciclicos como moduladores alostericos de receptores mglur5.
MX2011008857A (es) Derivados de oxiindol con actividad agonistica del receptor de motilina.

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: USE OF OPIOID RECEPTOR ANTAGONIST FOR GASTROINTESTINAL TRACT DISORDERS; FILING DATE: 14 MAR 2012; STATUS: REJECTED; TITLE: USE OF OPIOID RECEPTOR ANTAGONIST FOR GASTROINTESTINAL TRACT DISORDERS; FILING DATE: 13 NOV 2012; STATUS: REJECTED; TITLE: USE OF OPIOID RECEPTOR ANTAGONIST FOR GASTROINTESTINAL TRACT DISORDERS; FILING DATE: 17 JUN 2013; STATUS: REJECTED; TITLE: USE OF OPIOID RECEPTOR ANTAGONIST FOR GASTROINTESTINAL TRACT DISORDERS; FILING DATE: 17 JUN 2013; STATUS: PROPOSED;

Effective date: 20130625

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 SEP 2017 BY COMPUTER PACKAGES INC

Effective date: 20140910

LAPS Patent lapsed